ARCHIVES

Phase 0 Trials Signal FDA’s New Reliance On Biomarkers For Drug Development.

This article is from The Cancer Letter archive.

Vol. 32 No. 01 | January 13, 2006

Download PDF Visit The Full Archive

Related Articles

Cobimetinib-Zelboraf Therapy Increases OS In BRAF V600 Mutation-Positive Disease

October 31, 2014

Group Lobby To Add $200 Mil. To Cancer Budget

April 26, 1991

In Brief: Nominations Open For Bristol-Myers Award; New Surgical Oncology Chair At South Florida

September 7, 1984

NCI’s International Program Growing, With More Agreements, $8 Million In Contracts And Grants

August 8, 1975

UPCI Clarifies Agreement Between Eli Lilly And PCRN.

July 27, 2001

NIH-funded HapMap consortium publishes first phase of catalog.

October 28, 2005